CLYD BEACON TOPCO, INC.
Pharmaceutical Preparations · SEC CIK 2094256 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets28.1%
Debt / equity0.00x
Current ratio7.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q1*2026-03-31 | 2025Q32025-09-30 | 2025Q2*2025-06-30 | 2025Q1*2025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | $0 | — | — | — | — |
| R&D expense | $1.32M | — | — | $5.39M | — | — |
| SG&A expense | $5.14M | — | — | $5.17M | — | — |
| Operating income | -$6.46M | — | — | -$15.07M | — | — |
| Interest expense | $13,000 | — | — | $13,000 | — | — |
| Pretax income | -$6.13M | $0 | — | -$14.64M | — | — |
| Income tax | -$26,000 | $0 | — | -$71,000 | — | — |
| Net income | -$6.10M | $0 | -$5.53M | -$14.57M | -$21.13M | -$19.66M |
| EBITDA | -$6.26M | — | — | -$14.97M | — | — |
| EPS (basic) | -1.34 | 0.00 | — | -3.22 | — | — |
| EPS (diluted) | -1.34 | — | — | -3.22 | — | — |
| Weighted avg. shares (diluted) | 4.54M | 100 | — | 4.52M | — | — |
| Balance sheet | ||||||
| Cash & equivalents | $49.24M | $0 | — | $75.67M | — | — |
| Current assets | $52.97M | — | — | — | — | — |
| PP&E, net | $2.88M | — | — | — | — | — |
| Intangibles | $12.42M | — | — | — | — | — |
| Total assets | $70.80M | $0 | $0 | — | — | — |
| Current liabilities | $6.90M | — | — | — | — | — |
| Total liabilities | $19.90M | $0 | $0 | — | — | — |
| Shareholders' equity | $50.84M | $57.13M | $66.48M | $84.56M | $102.48M | $115.59M |
| Shares outstanding | 4.54M | 100 | 100 | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$21.59M | — | — | — | — | — |
| Investing cash flow | $116,000 | — | — | — | — | — |
| Financing cash flow | $0 | — | — | — | — | — |
| Depreciation & amortization | $200,000 | — | — | $100,000 | — | — |
| Stock-based compensation | $105,000 | — | — | -$415,000 | — | — |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.